Xenetic Biosciences Inc.

XBIO | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.61

-$0.38 (-12.71%)

Sep 22, 2026, 12:35 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-12.71%

(1D)

Rating

Updated: Aug 22, 2026

40.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $5.98M

1D Range

2.44 2.86

52W Range

1.87 13.93

Valuation (TTM)

PE -2.51

PB 1.13

EV/EBITDA -0.15

Valuation (NTM)

Forward PE N/A

Forward PEG 0.03

Price Target N/A

Cash Flow

FCF Yield -33.8%

SBC Adj. FCF Yield -34.9%

SBC Impact -3.3%

Margins

Gross Margin 100.0%

Operating Margin -81.0%

FCF Margin -70.9%

Growth (CAGR)

Revenue 3Y | 5Y 14.8% | 34.3%

Dil EPS 3Y | 5Y 44.9% | 36.3%

FCF 3Y | 5Y 20.2% | 21.6%

Returns

ROA -35.5%

ROE -40.6%

ROIC -43.5%

Financial Health

Net Cash

$6.47M

Current Ratio 7.43

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is...

Sector Healthcare

Industry Biotechnology

Employees 2

IPO Date Jun 29, 2016

Website www.xeneticbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.